摘要
目的探讨特布他林与异丙托溴铵雾化治疗支气管哮喘中重度急性发作的疗效及对肺功能的影响。方法抽取2019年1月~2020年9月收治的78例支气管哮喘中重度急性发作患者,随机数表法分为两组。对照组39例,予以患者常规治疗联合异丙托溴铵雾化吸入;试验组39例,对照组治疗基础上加用特布他林雾化吸入。比较观察两组临床症状消退时间、治疗前后肺功能指标与血清炎症因子水平。结果试验组喘息消退时间(3.15±1.72)d,咳嗽消退时间(5.06±1.41)d,哮鸣音消退时间(4.23±0.97)d,湿啰音消退时间(4.40±1.16)d,均早于对照组,治疗总有效率97.84%,高于对照组,差异有统计学意义(P<0.05)。试验组治疗后炎症因子指标CRP(6.15±1.36)mg/L、IL-6(42.94±8.06)pg/ml、IL-10(31.94±6.33)pg/ml,与对照组比较差异有统计学意义(P<0.05)。试验组治疗后肺功能指标FEV_(1)(2.37±0.65)L、PEF(4.31±1.06)L/s、FVC(3.61±0.50)L,均高于对照组,差异有统计学意义(P<0.05)。结论特布他林与异丙托溴铵联合雾化治疗支气管哮喘中重度急性发作,可以加速改善患者临床症状,缓解炎症反应,提高治疗效果,改善肺功能,利于疾病早期控制。
Objective To explore the effect of terbutaline and ipratropium bromide nebulization in the treatment of moderate to severe acute attacks of bronchial asthma and its influence on lung function.Methods A sample of 78 patients with moderate to severe acute attacks of bronchial asthma admitted to our hospital from January 2019 to September 2020 were divided into two groups by random number table.39 cases in the control group were treated with conventional treatment combined with ipratropium bromide nebulized inhalation;39 cases in the test group were treated with terbutaline nebulized inhalation on the basis of treatment.Compare and observe the time of clinical symptom resolution,lung function indexes and serum inflammatory factor levels before and after treatment in the two groups.Results The gasp regression time of the test group was(3.15±1.72)d,the cough resolution time(5.06±1.41)d,the wheezing sound regression time(4.23±0.97)d,and the wet rale extinction time(4.40±1.16)d,all earlier than that in the control group,the total effective rate of treatment was 97.84%,which was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the inflammatory factor indexes CRP(6.15±1.36)mg/L,IL-6(42.94±8.06)pg/ml,and IL-10(31.94±6.33)pg/ml of the experimental group were significantly different from those of the control group(P<0.05).After treatment,the lung function indexes FEV_(1)(2.37±0.65)L,PEF(4.31±1.06)L/s,and FVC(3.61±0.50)L of the test group were higher than those of the control group,and the difference was statistically significant(P<0.05).Conclusion Terbutaline and ipratropium bromide combined nebulization to treat moderate to severe acute attacks of bronchial asthma can accelerate the improvement of patients'clinical symptoms,alleviate inflammation,improve treatment effects,improve lung function,and facilitate early control of the disease.
作者
余准
黄锴川
林凯
YU Zhun;HUANG Kai-chuan;LIN Kai(Dafeng Hospital Shantou Chaoyang,Shantou 515154,China)
出处
《中国处方药》
2022年第7期114-116,共3页
Journal of China Prescription Drug
关键词
支气管哮喘
急性发作
特布他林
异丙托溴铵
雾化治疗
疗效
肺功能
Bronchial asthma
Acute attack
Terbutaline
Ipratropium bromide
Nebulization treatment
Efficacy
Pulmonary function
